NHS England has teamed up with three drug makers in its own massive effort to eradicate the disease. NHS England signed on with Gilead Sciences, Merck & Co. and AbbVie to purchase hepatitis C drugs at competitive prices and implement programs to find patients around the country. The government awarded Gilead “gold status” for hepatitis C drug procurement,
It was recently revealed that the UK would administer all babies with the hepatitis B vaccine to reduce the risk for young children, who are most risk should they catch the virus. Now, it has been revealed that manufacturing issues could cause severe shortages to administer the vaccine to those in need. Public Health England
Merck & Co has stated that the late-stage trials for its immunotherapy Keytruda to treat advanced melanoma has showed over half of the patients were alive two years after treatment had first began. The data gathered was part of multiple study results for its immunotherapy Keytruda in several cancer indications. Merck said the trial drug
Merck KGaA have today announced a new partnership with the Institute of Cancer Research (ICR) and the Wellcome Trust to develop cancer treatments. Merck KGaA’s Merck Serono unit will work with the UK organisations to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase (PARP) enzyme family. Specifically, the Institute of Cancer Research
Merck KGaA has revealed information regarding their new restructuring strategy and is targeting cost savings of 300 million euros at their drugs unit by 2014. Karl-Ludwig Kley, Chairman of the German organisation, noted that they face “unprecedented market shifts and increasing competition in key product areas [and] we are fortunate that we can address these
